However, the recent implementations of GLP‐1/GIP receptor co‐agonists in the treatment of metabolic diseases (Jastreboff et al., 2022; Rosenstock et al., 2021) and GLP‐2/GIP receptor co‐agonists for the treatment of bone disorders (Gabe, Skov‐Jeppesen, et al., 2022) have made it important to study these presumably prominent effects of GIP. This evidence concerns the gene GIP and metabolic disease.